Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-VALPROIC ACID | 250MG | CAPSULE | Resolved | 2022-09-23 | 2023-05-12 | 170115 |
| APO-VALPROIC ACID ORAL SOLUTION | 250MG | SOLUTION | Actual shortage | 2023-06-09 | 2024-12-05 | 194593 |
| APO-VALPROIC SYRUP | 50MG | SYRUP | Resolved | 2017-07-11 | 2017-08-18 | 15412 |
| APO-VALSARTAN | 80MG | TABLET | Resolved | 2017-03-10 | 2019-03-08 | 272 |
| APO-VALSARTAN | 160MG | TABLET | Resolved | 2017-03-11 | 2019-03-08 | 549 |
| APO-VALSARTAN | 320MG | TABLET | Resolved | 2017-03-11 | 2019-03-11 | 570 |
| APO-VALSARTAN | 40MG | TABLET | Resolved | 2017-03-11 | 2019-03-11 | 573 |
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Resolved | 2017-03-10 | 2019-03-21 | 263 |
| APO-VALSARTAN/HCTZ | 12.5MG 80MG | TABLET | Resolved | 2017-03-10 | 2019-03-21 | 266 |
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Resolved | 2017-03-10 | 2019-03-21 | 269 |
| APO-VALSARTAN/HCTZ | 25MG 160MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 546 |
| APO-VALSARTAN/HCTZ | 12.5MG 320MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 564 |
| APO-VALSARTAN/HCTZ | 25MG 320MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 567 |
| APO-VARDENAFIL | 5MG | TABLET | Resolved | 2021-05-25 | 2021-11-01 | 139854 |
| APO-VARDENAFIL | 10MG | TABLET | Resolved | 2021-05-25 | 2021-11-02 | 139857 |
| APO-VARDENAFIL | 20MG | TABLET | Resolved | 2021-04-05 | 2021-10-25 | 136817 |
| APO-VARDENAFIL | 10MG | TABLET | Resolved | 2020-04-13 | 2020-05-11 | 111960 |
| APO-VARDENAFIL | 20MG | TABLET | Resolved | 2020-04-15 | 2020-05-11 | 112198 |
| APO-VARENICLINE | 0.5MG | TABLET | Resolved | 2019-10-30 | 2019-11-18 | 97477 |
| APO-VARENICLINE | 0.5MG | TABLET | Resolved | 2020-02-05 | 2020-03-27 | 105367 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |